Lassa fever medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 8: Line 8:


==Medical Therapy==
==Medical Therapy==
* All persons suspected of Lassa fever infection should be admitted to [[Isolation (health care)|isolation]] facilities and their [[body fluids]] and [[excretion|excreta]] properly disposed of<ref name=CDC>{{cite web | title = The Centers for Disease Control and Prevention treatment | url =http://www.cdc.gov/vhf/lassa/treatment/index.html }}</ref>.
* All persons suspected of Lassa fever infection should be admitted to [[Isolation (health care)|isolation]] facilities and their [[body fluids]] and [[excretion|excreta]] properly disposed of.<ref name=CDC>{{cite web | title = The Centers for Disease Control and Prevention treatment | url =http://www.cdc.gov/vhf/lassa/treatment/index.html }}</ref>
* After extensive testing, it was determined that early administration of [[ribavirin]] is critical to success. Additionally, Ribavirin is almost twice as [[effective dose|effective]] when given [[intravenous]]ly as when taken by mouth.<ref>{{cite journal |author=Fisher-Hoch SP, McCormick JB |title=Lassa fever vaccine |journal=Expert review of vaccines |volume=3 |issue=2 |pages=189-97 |year=2004 |pmid=15056044 |doi=10.1586/14760584.3.4.S189}}</ref> Ribavirin is a [[prodrug]] which appears to interfere with [[viral replication]] by inhibiting [[RNA]]-dependent [[DNA Replication|nucleic acid synthesis]], although the precise [[mechanism of action]] is disputed.<ref>{{cite journal |author=Crotty S, Cameron C, Andino R |title=Ribavirin's antiviral mechanism of action: lethal mutagenesis? |journal=J. Mol. Med. |volume=80 |issue=2 |pages=86-95 |year=2002 |pmid=11907645 |doi=10.1007/s00109-001-0308-0}}</ref> The drug is relatively inexpensive, but the cost of the drug is still very high for many of those in poverty-stricken West African states. [[Fatality rate]]s are continuing to decline because of treatment with [[Ribavirin]]. [[Fluid replacement]], [[blood transfusion]] and fighting [[hypotension]] are usually required. [[Intravenous]] [[interferon]] [[therapy]] has also been used.
* After extensive testing, it was determined that early administration of [[ribavirin]] is critical to success. Additionally, Ribavirin is almost twice as [[effective dose|effective]] when given [[intravenous]]ly as when taken by mouth.<ref>{{cite journal |author=Fisher-Hoch SP, McCormick JB |title=Lassa fever vaccine |journal=Expert review of vaccines |volume=3 |issue=2 |pages=189-97 |year=2004 |pmid=15056044 |doi=10.1586/14760584.3.4.S189}}</ref> Ribavirin is a [[prodrug]] which appears to interfere with [[viral replication]] by inhibiting [[RNA]]-dependent [[DNA Replication|nucleic acid synthesis]], although the precise [[mechanism of action]] is disputed.<ref>{{cite journal |author=Crotty S, Cameron C, Andino R |title=Ribavirin's antiviral mechanism of action: lethal mutagenesis? |journal=J. Mol. Med. |volume=80 |issue=2 |pages=86-95 |year=2002 |pmid=11907645 |doi=10.1007/s00109-001-0308-0}}</ref> The [[drug]] is relatively inexpensive, but the cost of the [[drug]] is still very high for many of those in poverty-stricken West African states. [[Fatality rate]]s are continuing to decline because of treatment with [[Ribavirin]]. [[Fluid replacement]], [[blood transfusion]] and fighting [[hypotension]] are usually required. [[Intravenous]] [[interferon]] [[therapy]] has also been used.
* When Lassa fever infects [[pregnant]] women late in their [[third trimester]], it is necessary to [[abortion|abort]] the pregnancy for the mother to have a good chance of survival.<ref>{{cite journal |author=Price ME, Fisher-Hoch SP, Craven RB, McCormick JB |title=A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy |journal=BMJ |volume=297 |issue=6648 |pages=584–7 |year=1988 |pmid=3139220 |url=http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=3139220}}</ref>  This is due to the fact that the virus has an affinity for the [[placenta]] and other highly [[vascular]] tissues.  The [[fetus]] has only a one in ten chance of survival no matter what course of action is taken; hence focus is always on saving the life of the mother. Following [[abortion]], women should receive the same treatment as other Lassa fever patients.
* When Lassa fever infects [[pregnant]] women late in their [[third trimester]], it is necessary to [[abortion|abort]] the pregnancy for the mother to have a good chance of survival.<ref>{{cite journal |author=Price ME, Fisher-Hoch SP, Craven RB, McCormick JB |title=A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy |journal=BMJ |volume=297 |issue=6648 |pages=584–7 |year=1988 |pmid=3139220 |url=http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=3139220}}</ref>  This is due to the fact that the virus has an affinity for the [[placenta]] and other highly [[vascular]] tissues.  The [[fetus]] has only a one in ten chance of survival no matter what course of action is taken; hence focus is always on saving the life of the mother. Following [[abortion]], women should receive the same treatment as other Lassa fever patients.
* Shown below is a table summarizing the preferred treatment for Lassa fever<ref name="pmid11988060">{{cite journal| author=Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB et al.| title=Hemorrhagic fever viruses as biological weapons: medical and public health management. | journal=JAMA | year= 2002 | volume= 287 | issue= 18 | pages= 2391-405 | pmid=11988060 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11988060  }} </ref>.
* Shown below is a table summarizing the preferred treatment for Lassa fever.<ref name="pmid11988060">{{cite journal| author=Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB et al.| title=Hemorrhagic fever viruses as biological weapons: medical and public health management. | journal=JAMA | year= 2002 | volume= 287 | issue= 18 | pages= 2391-405 | pmid=11988060 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11988060  }} </ref>


{| class="wikitable" border="1" style="background:FloralWhite"
{| class="wikitable" border="1" style="background:FloralWhite"

Revision as of 13:12, 9 June 2015

Lassa fever Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Lassa fever from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lassa fever medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lassa fever medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lassa fever medical therapy

CDC on Lassa fever medical therapy

Lassa fever medical therapy in the news

Blogs on Lassa fever medical therapy

Directions to Hospitals Treating Lassa fever

Risk calculators and risk factors for Lassa fever medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Synonyms and keywords: Lassa hemorrhagic fever; LHF

Overview

Ribavirin, an antiviral drug, has been used with success in Lassa fever patients. It has been shown to be most effective when given early in the course of the illness. Patients should also receive supportive care consisting of maintenance of appropriate fluid and electrolyte balance, oxygenation and blood pressure, as well as treatment of any other complicating infections.

Medical Therapy

Optimal Treatment Duration of Treatment
Ribavarin

Loading dose: 30 mg/kg (max. 2g) IV


Concentration dose: 16 mg/kg (max. 1g) IV Q6H X 4 days, then 8 mg/kg (max. 500mg) IV Q8H X 6 days

10 days

References

  1. "The Centers for Disease Control and Prevention treatment".
  2. Fisher-Hoch SP, McCormick JB (2004). "Lassa fever vaccine". Expert review of vaccines. 3 (2): 189–97. doi:10.1586/14760584.3.4.S189. PMID 15056044.
  3. Crotty S, Cameron C, Andino R (2002). "Ribavirin's antiviral mechanism of action: lethal mutagenesis?". J. Mol. Med. 80 (2): 86–95. doi:10.1007/s00109-001-0308-0. PMID 11907645.
  4. Price ME, Fisher-Hoch SP, Craven RB, McCormick JB (1988). "A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy". BMJ. 297 (6648): 584–7. PMID 3139220.
  5. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB; et al. (2002). "Hemorrhagic fever viruses as biological weapons: medical and public health management". JAMA. 287 (18): 2391–405. PMID 11988060.


Template:WikiDoc Sources